NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Alembic Pharma Proposes Appointment of Rajkumar Baheti with ₹2.5 Cr Annual Professional Fees
Alembic Pharmaceuticals has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director effective April 1, 2026. The company is also seeking a special resolution to pay him professional fees up to ₹2.50 Crores per annum for one year, which is in addition to standard sitting fees. This fee exceeds the typical monetary thresholds prescribed under the Companies Act, requiring specific member approval. The e-voting period for these resolutions is scheduled from March 2 to March 31, 2026.
முக்கிய அம்சங்கள்
Proposed appointment of Mr. Rajkumar Baheti as Non-Executive Non-Independent Director starting April 1, 2026Approval sought for professional fees up to ₹2.50 Crores per annum plus applicable taxesThe professional fee arrangement is proposed for a period of one yearRemote e-voting period set from March 2, 2026, to March 31, 2026The professional fee resolution is a Special Resolution, requiring 75% majority for approval
👀 கவனிக்க வேண்டியவை
Investors should review the justification for the ₹2.5 crore professional fee in the explanatory statement and cast their votes by March 31, 2026.
Alembic Pharmaceuticals has received final USFDA approval for Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg strengths. The product is a generic version of GSK's Lamictal ODT and is used to treat seizures and bipolar I disorder. The addressable market for this product is estimated at US$ 27 million for the 12 months ending December 2025. This approval brings Alembic's total USFDA ANDA approvals to 235, including 216 final approvals.
முக்கிய அம்சங்கள்
Received final USFDA approval for Lamotrigine Orally Disintegrating Tablets USP in four strengths.Estimated market size for the product is US$ 27 million for the 12 months ending December 2025.Product is therapeutically equivalent to GlaxoSmithKline's Lamictal ODT.Cumulative USFDA ANDA approvals now stand at 235, with 216 final and 19 tentative approvals.
👀 கவனிக்க வேண்டியவை
This approval adds to Alembic's growing US generics portfolio and demonstrates steady regulatory execution. Investors should monitor the company's ability to monetize its 216 final approvals in the competitive US market.
Alembic Pharma Receives Final USFDA Approval for Efinaconazole Topical Solution (Market: $500M)
Alembic Pharmaceuticals has received final USFDA approval for Efinaconazole Topical Solution, 10%, a generic equivalent of Jublia. The product is indicated for the treatment of toenail fungus and addresses a significant market estimated at US$ 500 million for the twelve months ending December 2025. Alembic was notably one of the first ANDA applicants with a Paragraph IV certification for this product. This approval strengthens the company's US portfolio, bringing its total final USFDA approvals to 215.
முக்கிய அம்சங்கள்
Final USFDA approval received for Efinaconazole Topical Solution, 10%, targeting the toenail fungus market.The product addresses an estimated market size of US$ 500 million as of December 2025 per IQVIA data.Alembic was among the first ANDA applicants to submit with a Paragraph IV certification.Company now holds a cumulative total of 234 USFDA approvals, including 215 final approvals.
👀 கவனிக்க வேண்டியவை
This approval is a positive development for Alembic's US generics business and should support revenue growth in the upcoming fiscal years. Investors should monitor the company's ability to capture market share in this $500 million segment upon commercial launch.
Alembic Pharma Completes USFDA Inspection at Karakhadi Facility with 2 Observations
Alembic Pharmaceuticals has concluded an unannounced USFDA inspection at its Karakhadi Injectable Facility (F-3). The inspection, which took place from February 9 to February 18, 2026, resulted in two observations. Crucially, the company stated that none of the observations are related to data integrity, which is often a major concern for regulators. The company intends to respond to these observations within the required timeframe to maintain its compliance status.
முக்கிய அம்சங்கள்
USFDA conducted an unannounced cGMP inspection at the Karakhadi (F-3) injectable facility.The inspection spanned 10 days from February 9th to February 18th, 2026.The audit concluded with 2 observations, none of which pertain to data integrity.The company will submit a formal response to the observations within the stipulated time.
👀 கவனிக்க வேண்டியவை
Investors should monitor for further updates regarding the nature of the observations and the subsequent issuance of an Establishment Inspection Report (EIR). The absence of data integrity issues is a positive sign, suggesting the observations may be procedural.
Alembic Pharma Q3 FY26: Revenue Up 11% to ₹1,876 Cr; US Branded Launch Pivya Set for Q4
Alembic Pharmaceuticals reported a steady Q3 FY26 with revenue growing 11% YoY to ₹1,876 crores, driven by a robust 36% growth in Rest of World (ROW) markets and 6% growth in the US. EBITDA (pre-R&D) increased 20% to ₹464 crores, reflecting improved operating leverage despite gross margins moderating to 72% due to pricing pressures. A significant strategic milestone is the upcoming Q4 launch of 'Pivya,' the company's first branded product in the US market. While domestic growth remained tepid at 6%, management expects to return to market growth rates by Q1 FY27.
முக்கிய அம்சங்கள்
Revenue grew 11% YoY to ₹1,876 crores, with EBITDA (pre-R&D) rising 20% to ₹464 crores.US business grew 6% YoY with 7 new ANDA approvals and a strategic branded launch (Pivya) planned for Q4 FY26.ROW markets delivered strong performance with 36% YoY growth, offsetting pricing pressures in API and US generics.R&D spend increased 33% to ₹165 crores (9% of revenue) to support complex injectables and peptides.One-time exceptional provision of ₹42 crores recognized due to New Labour Code employee benefit changes.
👀 கவனிக்க வேண்டியவை
Investors should watch for the successful commercialization of 'Pivya' in the US, as it marks a shift toward higher-margin branded business. Monitor the domestic segment's recovery in FY27 to see if it aligns with management's market-growth targets.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Alembic Pharma Receives USFDA Final Approval for Parkinson's Disease Tablets
Alembic Pharmaceuticals has received final USFDA approval for its ANDA for Carbidopa, Levodopa, and Entacapone Tablets in six different strengths. These tablets are indicated for the treatment of Parkinson's disease and are therapeutically equivalent to the reference drug Stalevo. This approval marks a significant addition to the company's US portfolio, which now includes a cumulative total of 234 ANDA approvals. The company continues to leverage its vertically integrated R&D to expand its global generic footprint.
முக்கிய அம்சங்கள்
Received final USFDA approval for Carbidopa, Levodopa, and Entacapone Tablets in 6 dosage strengths.The product is a generic version of Orion Corporation's Stalevo Tablets used for Parkinson's disease.Alembic now has a cumulative total of 234 ANDA approvals, consisting of 214 final and 20 tentative approvals.The company maintains a strong domestic presence with a field force of over 5,500 personnel.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch and market share gains for this product in the US. The steady stream of ANDA approvals reinforces Alembic's long-term growth strategy in the generic pharmaceutical space.
Alembic Pharma Q3 Revenue Up 11% to ₹1,876 Cr; PAT Dips to ₹133 Cr on Exceptional Costs
Alembic Pharmaceuticals reported a 10.8% YoY growth in consolidated revenue to ₹1,876.31 crore for Q3 FY26. Net profit after non-controlling interests saw a slight decline of 3.9% YoY to ₹132.97 crore, primarily due to a one-time exceptional charge of ₹42.23 crore related to the implementation of new Labour Codes. Despite the profit dip, operating margins remained resilient at 16.42%, up from 16.00% in the previous year. The company also announced that Mr. Rajkumar Baheti will transition to a Non-Executive Director role effective April 2026.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.Net Profit (PAT) stood at ₹132.97 crore, impacted by a ₹42.23 crore exceptional provision for employee benefits.Operating Margin improved to 16.42% in Q3 FY26 compared to 16.00% in Q3 FY25.Debt-Equity ratio remains stable and healthy at 0.25x.Mr. Rajkumar Baheti appointed as Non-Executive Director effective April 1, 2026, following his tenure as Executive Director.
👀 கவனிக்க வேண்டியவை
The underlying business performance remains steady with healthy revenue growth; the profit decline is largely attributed to a non-recurring regulatory provision. Investors should focus on the company's margin sustainability and growth in its core pharmaceutical segments.
Alembic Pharma Q3 FY26 Revenue Up 11% to INR 18.76 Bn; Ex-US Generics Surges 36%
Alembic Pharmaceuticals reported a steady Q3 FY26 with revenue growing 11% YoY to INR 18.76 billion, driven largely by a 36% surge in Ex-US Generics. While EBITDA grew 14% to INR 3.08 billion, the bottom line was impacted by a one-time exceptional loss of INR 0.42 billion, leading to a slight 4% dip in PAT to INR 1.33 billion. The India Branded and US Generics segments showed moderate growth of 6% each, while the Animal Health division performed strongly with 22% growth. R&D investments remained significant at 9% of revenue, supporting a pipeline of 270 ANDA filings.
முக்கிய அம்சங்கள்
Total Revenue increased 11% YoY to INR 18.76 billion in Q3 FY26.Ex-US Generics revenue reached an all-time high of INR 4.06 billion, growing 36% YoY.EBITDA margins stood at 16%, with EBITDA growing 14% YoY to INR 3.08 billion.India Branded Business grew 6% to INR 6.52 billion, maintaining a 21st rank in the Indian Pharmaceutical Market.R&D expenditure increased to INR 1.65 billion, representing 9% of total revenue.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong momentum in Ex-US Generics and Animal Health, which are effectively diversifying the company's revenue streams. The core India and US businesses remain stable, though the impact of one-time exceptional items on the net profit should be monitored.
Alembic Pharma Q3 FY26: International Revenue Up 17% YoY to ₹954 Cr, Animal Health Grows 22%
Alembic Pharmaceuticals reported a steady Q3 FY26 with total international generic sales growing 17% YoY to ₹954 crore, driven by strong performance in Australia (65%) and Canada (32%). The US market saw a modest 6% growth to ₹553 crore, supported by new launches like Sacubitril Valsartan. Domestic branded formulations grew 6% YoY to ₹652 crore, with the Animal Health segment showing robust growth of 22%. The company continues its R&D momentum with 5 ANDA filings YTD and 7 launches planned for Q4 FY26.
முக்கிய அம்சங்கள்
International Generics revenue grew 17% YoY to ₹954 Cr, with Australia and EROW segments leading growth at 65% and 36% respectively.US Direct sales reached ₹478 Cr, a 7% YoY increase, aided by new product launches like Ticagrelor and Metoprolol.Domestic Branded Formulations grew 6% YoY to ₹652 Cr, significantly bolstered by a 22% surge in the Animal Health business.API business remained relatively flat with 2% YoY growth, totaling ₹263 Cr for the quarter.Strong R&D pipeline with 212 cumulative final ANDA approvals and 7 new products planned for launch in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of new US launches and the continued outperformance of the Animal Health segment. The steady growth in EROW markets provides a good hedge against US pricing pressures.
Alembic Pharma Receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion
Alembic Pharmaceuticals has secured final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, which is a generic version of Sandoz's Durezol. The product is used for treating inflammation and pain after ocular surgery and for endogenous anterior uveitis. This approval marks a continued expansion of the company's US product portfolio. With this addition, Alembic now holds a cumulative total of 233 USFDA approvals, including 213 final approvals.
முக்கிய அம்சங்கள்
Received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%Product is therapeutically equivalent to the reference listed drug Durezol by Sandoz Inc.Indicated for ocular surgery inflammation and endogenous anterior uveitisCompany's cumulative USFDA approvals reach 233 (213 final and 20 tentative)
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch and market share capture of this product in the US ophthalmic market. The steady stream of USFDA approvals remains a key driver for the company's international revenue growth.
Alembic Pharmaceuticals has received tentative approval from the USFDA for its Bosutinib Tablets, 400 mg, which is used to treat chronic myelogenous leukemia (CML). This strength adds to the company's existing final approvals for the 100 mg and 500 mg versions of the same drug. The market size for the 400 mg strength is estimated at approximately US$ 251 million for the twelve months ending September 2025. This approval brings Alembic's total USFDA ANDA count to 232, including 212 final and 20 tentative approvals.
முக்கிய அம்சங்கள்
Received USFDA tentative approval for Bosutinib Tablets, 400 mg strengthEstimated market size for the 400 mg strength is US$ 251 million as of September 2025Company already holds final approvals for 100 mg and 500 mg strengths of the same drugCumulative USFDA approvals reach 232 ANDAs, including 212 final approvalsThe drug is a therapeutic equivalent to the reference listed drug Bosulif by PF Prism C.V.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from tentative to final approval, which will allow for commercial launch in the US market. This development strengthens Alembic's oncology portfolio in the high-value US generic space.
Alembic Pharmaceuticals has received final USFDA approval for Travoprost Ophthalmic Solution, a generic version of Sandoz's Travatan Z. The product is used to treat elevated intraocular pressure in patients with glaucoma or ocular hypertension. This approval targets a US market size estimated at $61 million for the 12 months ending September 2025. This milestone brings Alembic's cumulative USFDA approvals to 232, including 212 final approvals.
முக்கிய அம்சங்கள்
Final USFDA approval for Travoprost Ophthalmic Solution USP, 0.004%.Targets an estimated annual US market size of $61 million per IQVIA data.Cumulative USFDA approvals reached 232 (212 final and 20 tentative).Therapeutically equivalent to the reference listed drug Travatan Z by Sandoz Inc.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive expansion of Alembic's US portfolio. Monitor the company's execution in capturing market share within this $61 million niche segment.
APLLTD Receives USFDA Final Approval for Loteprednol Etabonate Suspension
Alembic Pharmaceuticals Limited (APLLTD) has received USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%. This approval allows Alembic to market a generic version of Zylet Ophthalmic Suspension. Alembic was granted Competitive Generic Therapy (CGT) designation and is eligible for 180 days of CGT exclusivity upon commercialization. This brings Alembic's cumulative ANDA approvals to 231, comprising 211 final approvals and 20 tentative approvals.
முக்கிய அம்சங்கள்
Received USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%ANDA is therapeutically equivalent to Zylet Ophthalmic Suspension, 0.5%/0.3%Granted Competitive Generic Therapy (CGT) designationEligible for 180 days of CGT exclusivity upon commercializationAlembic has a cumulative total of 231 ANDA approvals from USFDA
👀 கவனிக்க வேண்டியவை
This approval is a positive sign for Alembic, potentially increasing revenue through generic drug sales. Investors should monitor the commercialization and market share gains from this product.
Alembic Pharmaceuticals Announces Resignation of Head-International Business Formulations
Alembic Pharmaceuticals Limited (APLLTD) has announced the resignation of Mr. Prashant Khandelwal, the Head of International Business Formulations. The resignation is effective from the close of business hours on December 1, 2025. As a key member of the senior management team, Mr. Khandelwal was responsible for overseeing the company's global formulation business. The company has complied with SEBI Regulation 30 in disclosing this leadership change.
முக்கிய அம்சங்கள்
Mr. Prashant Khandelwal resigned from his position as Head-International Business Formulations.The resignation became effective as of December 1, 2025, after business hours.The disclosure was made in accordance with SEBI (LODR) Regulations, 2015.The international business segment is a critical growth driver for Alembic Pharmaceuticals.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of a successor to ensure continuity in the international business segment. No immediate portfolio changes are recommended based solely on this management exit.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
